Many on Wall Street said the company overpaid in its purchase of Frutarom and its merger with DuPont’s Nutrition & Biosciences division in 2018 and 2019. The $7.1 billion Frutarom deal, in particular, ...
“I can assure you, we will not do anything like another Frutarom,” he said, emphasizing a commitment to acquisitions that align with IFF’s strategic priorities. “We’re looking at bolt-on ...
Its portfolio has changed in recent years with the acquisition of DuPont's nutrition and biosciences business in 2021 and Frutarom in 2018. IFF holds an enviable portfolio focused on value-added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback